OBESITY THE PARADOX IN CARDIOVASCULAR DISEASE AND CRITICAL ILLNESS: A NARRATIVE REVIEW

Background: Obesity, affecting approximately 20% of intensive care unit admissions and a substantial proportion of cardiovascular disease patients, is traditionally recognized as a major risk factor for adverse health outcomes (1). The "obesity paradox" describes the counterintuitive observation of improved survival in overweight and mildly obese patients with established cardiovascular disease or critical illness. Objective: To comprehensively examine the obesity paradox in cardiovascular disease and critical illness, evaluating epidemiological evidence, mechanistic hypotheses, methodological limitations, and therapeutic implications. Methods: A systematic literature search was conducted using PubMed, MEDLINE, Embase, and Cochrane Library databases for articles published between January 2015 and March 2026. Search terms included "obesity paradox," "body mass index," "cardiovascular disease," "heart failure," "critical illness," "sepsis," and "mortality." Narrative synthesis was performed on included studies. Conclusion: The obesity paradox is a complex phenomenon with plausible biological underpinnings but significant methodological limitations. It should not be interpreted as evidence against weight management; rather, it highlights the need for nuanced, phenotype-specific approaches incorporating body composition and fitness assessment.

• World Health Organization. Obesity and overweight fact sheet. Geneva: WHO, 2024.
• Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med., 2019; 381(25): 2440-2450.
• Powell-Wiley TM, Poirier P, Burke LE, Despres JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 2021; 143(21): e984-e1010.
• Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction. Cardiovasc Res., 2023; 118(18): 3434-3450.
• Van Woerden G, van Veldhuisen DJ, Westenbrink BD, de Boer RA, Rienstra M, Gorter TM. Connecting epicardial adipose tissue and heart failure. Eur J Heart Fail, 2022; 24(12): 2238-2250.
• Alebna PL, Kim JH, Mandavia R, Parikh KS, Velazquez EJ. Update on obesity, the obesity paradox, and obesity management in heart failure. Prog Cardiovasc Dis., 2024; 82: 34-42.
• Schetz M, De Jong A, Deane AM, Druml W, Hemelaar P, Pelosi P, et al. Obesity in the critically ill: a narrative review. Intensive Care Med., 2025; 51(1): 3-18.
• Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med., 2023; 389(12): 1069-1084.
• Prado CM, Gonzalez MC, Heymsfield SB. Body composition phenotypes and obesity paradox. Curr Opin Clin Nutr Metab Care., 2015; 18(6): 535-551.
• Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT-proBNP. Int J Cardiol, 2014; 176(3): 611-617.
• Zamora E, Lupon J, de Antonio M, Urrutia A, Coll R, Diez C, et al. Does body mass index influence mortality in patients with heart failure? Rev Esp Cardiol, 2007; 60(11): 1127-1134.
• Banack HR, Kaufman JS. The obesity paradox: understanding the effect of obesity on mortality among individuals with cardiovascular disease. Prev Med., 2014; 62: 96-102.
• Fröhlich H, Frankenstein L, Tager T, Schellberg D, Katus HA, Grundtvig M, et al. The obesity paradox in heart failure. Cardiology, 2022; 147(5-6):           529-538.
• Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrom SZ, Davies MJ, et al. Semaglutide in obesity-related HFpEF: pooled analysis of STEP-HFpEF trials. Lancet, 2024; 403(10437): 1635-1646.
• Andrianto A, Al-Farabi MJ, Nugraha RA, Marsudi BA, Azmi Y. The obesity paradox exists in Asia. Tzu Chi Med J., 2024; 36(4): 387-395.
• Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med., 2023; 389(24): 2221-2232.
• Ball L, Serpa Neto A, Pelosi P. Obesity and survival in critically ill patients with ARDS. Curr Opin Crit Care., 2017; 23(1): 52-59.
• Stefan N, Haring HU, Hu FB, Schulze MB. Metabolically healthy obesity. Lancet Diabetes Endocrinol, 2013; 1(2): 152-162.
• McAuley PA, Blaha MJ, Keteyian SJ, Brawner CA, Al Rifai M, Dardari ZA, et al. Fitness, fatness, and mortality. Am J Med., 2016; 129(9): 960-965.
• Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure. Cardiovasc Res., 2023; 118(17): 3272-3287.
• Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Koladia N, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med., 2025; 392(5): 427-437.
• Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep., 2013; 10(4): 401-410.
• Mechanick JI, Apovian C, Brethauer S, Garvey WT, Joffe AM, Kim J, et al. Clinical practice guidelines for bariatric procedures. Surg Obes Relat Dis., 2020; 16(2): 175-247.
• Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease. J Am Coll Cardiol, 2009; 53(21): 1925-1932.
• Kittleson MM, Gilbert ON, Vaduganathan M, Albert MA, Carnicelli AP, Chan PS, et al. ACC scientific statement on obesity control strategies in heart failure. J Am Coll Cardiol, 2025; 85(24):            2587-2612.